A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells

Recruiting

GM T Cell TherapyA Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells

Sponsor:

Regeneron Pharmaceuticals

Code:

NCT06798298

Conditions

Long Term Safety Following GM T Cell Therapy

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Non-interventional

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-27. This information was provided to ClinicalTrials.gov by Regeneron Pharmaceuticals on 2025-10-07.